CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 414 target
Drug / intervention
KL590586 Capsuledrug
Likely dose
KL590586 Capsule 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05265091
NCT05265091Phase 2ActiveOn Track
CompareCT.gov

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·interventional·Posted Mar 3, 2022·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating KL590586 Capsule for Advanced Solid Tumor. Active but no longer recruiting, targeting 414 participants across 1 site.

Detailed Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 2Active
202220232024202520262027
First PostedMar 3, 2022
Enrollment StartSep 15, 2021
Primary CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 4.3 years agoPrimary completion in 6 months

Interventions

KL590586 Capsuledrug

Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule